65/100 · Elevated
Manufactured by Novo Nordisk
Liraglutide Adverse Events: Nausea and Pancreatitis Concerns
79,181 FDA adverse event reports analyzed
Last updated: 2026-05-12
LIRAGLUTIDE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Novo Nordisk. Based on analysis of 79,181 FDA adverse event reports, LIRAGLUTIDE has a safety score of 65 out of 100. This moderate score indicates a notable volume of adverse event reports that patients and providers should be aware of. The most commonly reported adverse reactions for LIRAGLUTIDE include NAUSEA, BLOOD GLUCOSE INCREASED, VOMITING, DIARRHOEA, PANCREATITIS. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for LIRAGLUTIDE.
Liraglutide has a safety concern score of 65 out of 100, placing it in the elevated concern category based on analysis of FDA adverse event data. The FDA has received approximately 79,181 adverse event reports for this medication, which is primarily manufactured by Novo Nordisk.
The most commonly reported adverse events include Nausea, Blood Glucose Increased, Vomiting. Of classified reports, 47.8% were designated as serious by the FDA, meaning they involved hospitalization, disability, or other significant medical outcomes. Nausea and vomiting are the most common gastrointestinal side effects.
Pancreatitis is a significant safety concern, with 2,318 reports. Weight loss is a common effect, with 2,076 reports of weight decreased. Serious adverse events account for 47.8% of all reports.
Patients taking Liraglutide should monitor for the commonly reported side effects and contact their healthcare provider if they experience any unusual symptoms. Liraglutide can cause gastrointestinal issues and should be used with caution in patients with a history of pancreatitis. This analysis is based on voluntary FDA adverse event reports and should not replace professional medical advice.
Liraglutide received a safety concern score of 65/100 (elevated concern). This is based on a 47.8% serious event ratio across 47,844 classified reports. The score accounts for 79,181 total adverse event reports and 100 distinct reaction types. This elevated score indicates a notable proportion of serious adverse events and warrants careful monitoring.
Adverse event reports by sex: Female: 28,937, Male: 16,114, Unknown: 149. The most frequently reported age groups are age 65 (1,105 reports), age 64 (1,018 reports), age 62 (1,017 reports). These demographics reflect reporting patterns and may not represent the full patient population.
Out of 47,844 classified reports for LIRAGLUTIDE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
Liraglutide can cause gastrointestinal issues and should be used with caution in patients with a history of pancreatitis.
If you are taking Liraglutide, here are important things to know. The most commonly reported side effects include nausea, blood glucose increased, vomiting, diarrhoea, pancreatitis. While many of these may be mild and temporary, you should contact your healthcare provider if any symptoms are severe or persistent. Monitor for signs of pancreatitis, such as severe abdominal pain, especially in the upper abdomen. Report any serious adverse events to the FDA's MedWatch program. If you experience a serious adverse reaction, seek emergency medical attention immediately or call 911. You can report side effects to the FDA's MedWatch program at 1-800-FDA-1088.
The FDA continues to monitor Liraglutide for safety, particularly for pancreatitis and serious adverse events.
The FDA has received approximately 79,181 adverse event reports associated with Liraglutide. These reports come from healthcare professionals, consumers, and manufacturers through the FDA Adverse Event Reporting System (FAERS). Note that the number of reports does not directly indicate the frequency of side effects, as adverse events are voluntarily reported and may be underrepresented.
The most frequently reported adverse events for Liraglutide include Nausea, Blood Glucose Increased, Vomiting, Diarrhoea, Pancreatitis. By volume, the top reported reactions are: Nausea (7,005 reports), Blood Glucose Increased (3,875 reports), Vomiting (3,364 reports). These figures reflect FDA adverse event reports and may not represent the true incidence rate of these side effects in all patients taking Liraglutide.
Out of 47,844 classified reports, 22,853 (47.8%) were classified as serious and 24,991 as non-serious. The FDA classifies an event as "serious" if it results in death, hospitalization, disability, or other medically significant outcomes. A higher serious-event ratio warrants closer attention but does not necessarily mean the drug is unsafe.
Adverse event reports for Liraglutide break down by patient sex as follows: Female: 28,937, Male: 16,114, Unknown: 149. This distribution reflects reporting patterns rather than actual risk differences between groups. Reporting rates can be influenced by prescribing patterns, disease demographics, and reporting behavior.
The most frequently reported age groups for Liraglutide adverse events are: age 65: 1,105 reports, age 64: 1,018 reports, age 62: 1,017 reports, age 60: 1,013 reports, age 63: 1,000 reports. Age-related reporting patterns can reflect both the demographics of the patient population and potential age-related susceptibility to certain side effects.
The primary manufacturer associated with Liraglutide adverse event reports is Novo Nordisk. Multiple manufacturers may produce generic versions of this drug. The manufacturer listed reflects the most frequently reported brand in FDA adverse event data.
Beyond the most common reactions, other reported adverse events for Liraglutide include: Weight Decreased, Decreased Appetite, Headache, Off Label Use, Fatigue. Less common side effects can still be clinically significant. Patients should report any unusual symptoms to their healthcare provider.
You can report adverse events from Liraglutide to the FDA through their MedWatch program at www.fda.gov/medwatch, by calling 1-800-FDA-1088, or by completing Form FDA 3500. Healthcare professionals, consumers, and manufacturers can all submit reports. Reporting helps the FDA monitor drug safety after approval.
Liraglutide has a safety concern score of 65 out of 100 (elevated concern). This score is calculated from the ratio of serious to non-serious adverse events, the diversity of reported reactions, and the overall volume of reports relative to usage. Nausea and vomiting are the most common gastrointestinal side effects.
Key safety signals identified in Liraglutide's adverse event data include: Pancreatitis is a key safety signal, with 2,318 reports.. Nausea and vomiting are frequent, with 7,005 and 3,364 reports respectively.. Weight changes, both gain and loss, are notable, with 1,187 and 2,076 reports respectively.. These signals are derived from patterns in FDA reports and should be discussed with a healthcare provider for personalized assessment.
Liraglutide can cause gastrointestinal issues and should be used with caution in patients with a history of pancreatitis. Always inform your healthcare provider about all medications, supplements, and over-the-counter drugs you are taking before starting Liraglutide.
Monitor for signs of pancreatitis, such as severe abdominal pain, especially in the upper abdomen. Report any serious adverse events to the FDA's MedWatch program.
Liraglutide has 79,181 adverse event reports on file with the FDA. Pancreatitis is a significant safety concern, with 2,318 reports. The volume of reports for Liraglutide reflects both the drug's usage level and the vigilance of the reporting community.
The FDA continues to monitor Liraglutide for safety, particularly for pancreatitis and serious adverse events. For the most current regulatory information, check the FDA's drug labeling database or consult your pharmacist.
Explore other medications manufactured by Novo Nordisk and compare their safety profiles:
The following drugs share commonly reported adverse reactions with LIRAGLUTIDE:
Drugs related to LIRAGLUTIDE based on therapeutic use, drug class, or shared indications: